Ministry of health and family welfare, Government of India has approved the commencement of Materiovigilance Programme of India (MvPI) on July 6, 2015 to monitor the safety of medical devices in the country. For MvPI, Indian Pharmacopoeia Commission (IPC) functions as National Coordination Centre (NCC) since 2018. Sree Chitra Tirunal Institute for Medical Sciences & Technology (SCTIMST), Thiruvananthapuram acts as National Collaboration Centre, National Health System Resource Centre (NHSRC), New Delhi, acts as Technical support partner and Central Drugs Standards Control Organization (CDSCO), New Delhi, supports MvPI with experience of functioning as National regulator.
MvPI aims to collect data on medical device related adverse events systematically and scientifically analyze them to aid in regulatory decisions and recommendations on safe use of medical devices. MvPI monitors medical device-associated adverse events (MDAE), create awareness among healthcare professionals about the importance of MDAE reporting in India and to evaluate the benefit-risk ratio of medical devices. MvPI generates independent, evidence-based recommendations on the safety of medical devices and to communicate the findings to all key stakeholders.
Dr.G.N.Singh DCG(I) along with other experts during the launch of MvPI.